drugset / Trial / NCT04929652
Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The objective is to investigate the efficacy and safety of Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2022-06
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 200 mg | Oral |
| Subject | Surufatinib | Small molecule | 250 mg | Oral |
| Subject | Surufatinib | Small molecule | 300 mg | Oral |
| Background | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Irinotecan | Small molecule | 200 mg/m2 | Intravenous |
| Background | sargramostim | Protein / enzyme biologic | 5 ug/kg | — |